Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
376 studies found for:    gefitinib
Show Display Options
Rank Status Study
1 Unknown  Hydroxychloroquine and Gefitinib to Treat Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Gefitinib, Hydroxychloroquine
2 Completed
Has Results
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
Conditions: Recurrent Skin Cancer;   Squamous Cell Carcinoma of the Skin
Interventions: Drug: Gefitinib;   Radiation: Radiotherapy;   Procedure: Conventional surgery;   Other: laboratory biomarker analysis
3 Completed
Has Results
Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Gefitinib retreatment
4 Active, not recruiting High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Gefitinib
5 Completed Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Condition: Myelogenous Leukemia, Acute
Intervention: Drug: gefitinib
6 Completed
Has Results
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Conditions: Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligodendroglioma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliomatosis Cerebri;   Untreated Childhood Gliosarcoma;   Untreated Childhood Oligodendroglioma
Interventions: Drug: gefitinib;   Radiation: radiation therapy;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Recruiting A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Condition: EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
Interventions: Drug: Apatinib;   Drug: Gefitinib;   Drug: Placebo
8 Unknown  First Line Gefitinib by FDG-PET Metabolic Response
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Gefitinib
9 Completed Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
Condition: Head and Neck Cancer
Intervention: Drug: Gefitinib
10 Recruiting Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
Conditions: Non-small Cell Lung Cancer;   Effects of Chemotherapy
Interventions: Drug: Gefitinib group;   Drug: Vinorelbine, Ifosfamide, Mesna
11 Unknown  Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Docetaxel
12 Completed Gefitinib in Treating Children With Refractory Solid Tumors
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: gefitinib;   Other: pharmacological study;   Other: laboratory biomarker analysis
13 Unknown  Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC
Condition: Non-small-cell Lung Cancer
Intervention: Drug: Gefitinib
14 Completed Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Interventions: Drug: simvastatin;   Drug: gefitinib only
15 Completed A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: celecoxib, gefitinib
16 Completed Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Condition: Thoracic Neoplasms
Interventions: Drug: erlotinib;   Drug: gefitinib
17 Completed Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Gefitinib and Nimotuzumab;   Drug: Gefitinib
18 Suspended Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: gefitinib
19 Completed
Has Results
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Gefitinib;   Drug: Placebo
20 Completed Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: gefitinib;   Radiation: radiation therapy;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years